Breaking news

Should AI Decide Who Gets A Kidney? New Study Exposes A Sharp Divide With Human Doctors

If artificial intelligence were making the call, would you trust it to decide who receives a life-saving transplant?

A new study suggests that when large language models are asked to weigh scarce medical resources, they do not think like human doctors — and in some cases, they do not think like humans at all.

AI Weighs The Wrong Things, Or At Least Different Ones

Researchers at Penn State University tested large language models using hypothetical kidney-allocation scenarios drawn from prior human research. In each case, the AI had to choose between two eligible patients competing for a single available kidney.

The patients were defined by traits such as age, health and drinking habits, allowing researchers to compare how AI systems prioritized competing factors against how people had previously made the same decisions in human studies.

The results were striking. Human participants tended to place more weight on age, often favoring younger patients. By contrast, many AI models gave greater priority to lower alcohol consumption. More importantly, the models frequently narrowed complex ethical judgments to a single attribute, while humans tended to consider the broader context.

“AI chatbots often diverge from human values in how they weigh a patient’s traits,” said Hadi Hosseini, who led the study at Penn State University. “They fixate on a single factor, like drinking habits, rather than balancing multiple considerations the way people do.”

Indecision Is A Human Feature — And An AI Weakness

Another key difference was hesitation. Human respondents often recognized that there is no single objectively correct answer in a scarcity decision such as organ allocation. Their choices reflected nuance, ambiguity and moral trade-offs.

The models, by contrast, typically committed to one answer with little sign of uncertainty.

That may seem efficient, but in high-stakes settings, certainty is not always a virtue. Decisions about kidneys, jobs or other scarce resources often involve values that cannot be reduced to a clean formula. Humans often absorb that ambiguity through discussion, debate and institutional safeguards. AI systems, the researchers argue, tend to skip over it.

“When we allocate something scarce, whether it’s a kidney, a job or access to some other resource, there isn’t always a single objectively correct answer,” said John Dickerson, chief executive officer at Mozilla.ai, who collaborated on the study. “Humans recognize that ambiguity and codify it via open debate into the allocative process. AI models often don’t.”

Why This Matters For Healthcare

The study arrives at a moment when AI is moving rapidly into healthcare, where it is already being used to support diagnosis, clinical workflows, treatment planning and the allocation of scarce medical resources.

That growing role makes the question of alignment especially urgent. In healthcare, the issue is not simply whether a model can produce an answer, but whether that answer reflects the moral standards and professional judgment that society expects from life-altering decisions.

Kidney allocation is a particularly sensitive example because it sits at the intersection of ethics, medicine and resource scarcity. Choosing one patient over another is never just a technical decision; it is a judgment about fairness, need, prognosis and social values.

“The ethical stakes are high, and AI’s role in such life-altering decisions requires deep reflection,” Hosseini said. “Moral decisions in settings like organ allocation directly determine who lives and who dies, so getting AI’s role in them right isn’t optional.”

The Broader Debate Over AI And Moral Judgment

The researchers say their findings speak to a wider debate over whether AI can make moral decisions — or whether it can ever truly align with human values.

That debate is no longer theoretical. As organizations increasingly rely on AI systems for recommendations, rankings and triage decisions, understanding how those systems reason has become a practical governance issue.

The study does not argue that AI should replace professional judgment in medicine. If anything, it reinforces the opposite conclusion: the more consequential the decision, the more important it is to understand where AI diverges from human reasoning.

In healthcare, as in business and public policy, the danger is not only that AI may be wrong. It may also be confidently, efficiently and consistently wrong in ways that humans would immediately question.

LVMH Revenue Rises, But China Weakness Continues To Weigh On Luxury Giant

A Softer Quarter Exposes The Limits Of Luxury’s Recovery

LVMH, the world’s largest luxury group and parent of Louis Vuitton, Dior, Celine and Hennessy, reported revenue of €18.5 billion in the three months to the end of September, underscoring both the scale of its business and the pressure building across parts of the luxury market.

The company’s revenue rose 1.2% year on year in the third quarter, following a 0.1% increase in the second quarter and a 5.9% decline in the first. The trajectory points to stabilization, but not yet to a convincing rebound.

Organic Growth Misses Expectations

Organic sales growth, which strips out currency effects and portfolio changes, slowed to 1% in the third quarter from 3% in the previous quarter. That result fell short of market expectations and reinforced concerns that the luxury cycle remains uneven.

For the first nine months of the year, LVMH generated sales of €57.1 billion, with organic growth of 2%.

In its statement, the company highlighted the breadth of its portfolio, saying that diversification continues to provide resilience in an uncertain geopolitical and economic environment. That remains one of LVMH’s defining strengths: when one category weakens, another can help offset the downturn.

China Remains The Key Pressure Point

LVMH said sales performed well in the United States, Europe and Japan, but conditions in China remained less favorable. That matters because the country has long been one of the most important growth engines for global luxury brands.

The fashion and leather goods division, LVMH’s most closely watched unit, saw organic sales fall 5% as weaker demand in China weighed on performance. Deutsche Bank said the decline was steeper than the roughly 2% drop expected by analysts.

The segment had delivered its first organic sales gain in two years in the previous quarter, making the latest retreat a notable setback.

Brand Equity Faces A Test In China

The quarter also highlighted the reputational risks facing global brands in China. Louis Vuitton drew criticism after suing local tea company Molly Tea over logo copying. Although the company won the case, the dispute sparked social media backlash and boycott calls, adding another layer of pressure to an already fragile environment.

For a company built on scarcity, aspiration and brand discipline, perception is an asset as valuable as inventory. In a market as digitally connected as China, that asset can shift quickly.

Mixed Performance Across The Portfolio

Not every division weakened. LVMH’s selective retailing business, which includes Sephora, posted an 8% organic sales increase. Watches and jewellery, along with wines and spirits, both recorded 6% organic gains.

That broad mix is precisely what has historically given LVMH an advantage over rivals: it can absorb softness in one category without relying on a single growth driver.

Analysts See A Longer Recovery Ahead

Deutsche Bank analysts said the results could lead to further cuts in earnings forecasts for the second half of 2026 and 2027. They added that it is difficult to see what could improve investor sentiment in the near term.

Still, the bank framed the weakness as cyclical rather than structural. In its view, recovery is taking longer because Chinese demand remains subdued, but the problem does not appear to reflect a permanent deterioration in the brand franchise. Analysts said ongoing brand initiatives are beginning to show results, though improvements are likely to remain gradual.

Investor Pressure Continues To Mount

LVMH’s share price has fallen nearly 40% since the start of the year. In September, L’Oréal overtook the group as France’s most valuable listed company, a symbolic shift that captures how sharply sentiment has changed.

Shares in LVMH were down more than 1.6% in Paris around 10 a.m. CEST following the release.

Aretilaw firm
eCredo
Uol
The Future Forbes Realty Global Properties

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter